Insider trade

Processa Pharmaceuticals (PCSA): CEO received 9,384 units

George K Ng, CEO at Processa Pharmaceuticals, reported a grant / award of 9,384 units.

9,384
Derivative units
Traded
Jul 26, 2026
Filed
Jul 29, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. May 29, 2026Insider · 5 peopleInsiders: 5 purchases (~$25K)
  2. Jun 15, 2026Insider · 5 peopleInsiders: 5 purchases (~$25K)
  3. Jun 30, 2026Insider · 4 peopleInsiders: 4 purchases (~$20K)
  4. Jul 1, 2026Insider · 5 insiders in a week, 4th time since 2020CEO purchased ~$5.9K of PCSA shares in the open market
  5. Jul 23, 2026Company filing · Form 8-K · Material agreement, Agreement endedCompleted buying or selling a business or assets, and changed a top executive or board member (and 5 more items)“Appointment of Directors In accordance with the Merger Agreement, on July 28, 2026, effective immediately after the First Effective Time, Sheila Gujrathi was appointed to the Board as a director.”

What came next

  1. Jul 30, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On July 30, 2026, Processa Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, shareholders of the Company approved an amendment to Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan (“Incentive Plan”) to increase the number of shares available for issuance under the plan by 200,000 shares.”
  2. Nov 2, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On November 2, 2026, the Board approved the appointment of Gregory J. Flesher as Chief Operating Officer of the Company, effective November 4, 2026 (the “ Start Date ”).”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Processa Pharmaceuticals

OQRO holds no insider, Congress, fund or contract record for Processa Pharmaceuticals dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PCSA page.

Other recent filings by George K Ng, Chief Executive Officer

The full history of George K Ng, Chief Executive Officer is on the profile page.

How this filing works

Explore the data

Common questions

Which Processa Pharmaceuticals (PCSA) insider traded, and how much?

George K Ng, CEO at Processa Pharmaceuticals, reported a grant / award of 9,384 units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Jul 26, 2026. Filed: Jul 29, 2026. That is 3 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

Does this mean PCSA stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Processa Pharmaceuticals

Everything OQRO holds on this company is on its PCSA page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data